dalteparin has been researched along with Polycythemia Vera in 1 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Polycythemia Vera: A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| O'Meara, AC | 1 |
| Demarmels Biasiutti, F | 1 |
| Heizmann, M | 1 |
1 other study available for dalteparin and Polycythemia Vera
| Article | Year |
|---|---|
Fondaparinux as an alternative therapy in heparin-induced delayed-type hypersensitivity skin lesions.
Topics: Aged; Anticoagulants; Drug Eruptions; Fondaparinux; Humans; Hypersensitivity, Delayed; Injections, S | 2007 |